IBDEI1FZ ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23059,1,4,0)
 ;;=4^K91.32
 ;;^UTILITY(U,$J,358.3,23059,2)
 ;;=^5151429
 ;;^UTILITY(U,$J,358.3,23060,0)
 ;;=H59.323^^105^1166^185
 ;;^UTILITY(U,$J,358.3,23060,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23060,1,3,0)
 ;;=3^Postproc Hemor/Hematom,Bil Eye/Adnexa After Oth Proc
 ;;^UTILITY(U,$J,358.3,23060,1,4,0)
 ;;=4^H59.323
 ;;^UTILITY(U,$J,358.3,23060,2)
 ;;=^5006423
 ;;^UTILITY(U,$J,358.3,23061,0)
 ;;=N99.85^^105^1166^174
 ;;^UTILITY(U,$J,358.3,23061,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23061,1,3,0)
 ;;=3^Post Endometrial Ablation Syndrome
 ;;^UTILITY(U,$J,358.3,23061,1,4,0)
 ;;=4^N99.85
 ;;^UTILITY(U,$J,358.3,23061,2)
 ;;=^5158110
 ;;^UTILITY(U,$J,358.3,23062,0)
 ;;=I05.0^^105^1167^48
 ;;^UTILITY(U,$J,358.3,23062,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23062,1,3,0)
 ;;=3^Rheumatic Mitral Stenosis
 ;;^UTILITY(U,$J,358.3,23062,1,4,0)
 ;;=4^I05.0
 ;;^UTILITY(U,$J,358.3,23062,2)
 ;;=^5007041
 ;;^UTILITY(U,$J,358.3,23063,0)
 ;;=I08.0^^105^1167^49
 ;;^UTILITY(U,$J,358.3,23063,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23063,1,3,0)
 ;;=3^Rheumatic Mitral/Aortic Valve Disorders
 ;;^UTILITY(U,$J,358.3,23063,1,4,0)
 ;;=4^I08.0
 ;;^UTILITY(U,$J,358.3,23063,2)
 ;;=^5007052
 ;;^UTILITY(U,$J,358.3,23064,0)
 ;;=I25.10^^105^1167^7
 ;;^UTILITY(U,$J,358.3,23064,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23064,1,3,0)
 ;;=3^Athscl Hrt Dis,Nat Cor Art w/o Ang Pctrs
 ;;^UTILITY(U,$J,358.3,23064,1,4,0)
 ;;=4^I25.10
 ;;^UTILITY(U,$J,358.3,23064,2)
 ;;=^5007107
 ;;^UTILITY(U,$J,358.3,23065,0)
 ;;=I31.9^^105^1167^42
 ;;^UTILITY(U,$J,358.3,23065,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23065,1,3,0)
 ;;=3^Pericardium Disease,Unspec
 ;;^UTILITY(U,$J,358.3,23065,1,4,0)
 ;;=4^I31.9
 ;;^UTILITY(U,$J,358.3,23065,2)
 ;;=^5007165
 ;;^UTILITY(U,$J,358.3,23066,0)
 ;;=I34.1^^105^1167^36
 ;;^UTILITY(U,$J,358.3,23066,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23066,1,3,0)
 ;;=3^Nonrheumatic Mitral Valve Prolapse
 ;;^UTILITY(U,$J,358.3,23066,1,4,0)
 ;;=4^I34.1
 ;;^UTILITY(U,$J,358.3,23066,2)
 ;;=^5007170
 ;;^UTILITY(U,$J,358.3,23067,0)
 ;;=I35.0^^105^1167^35
 ;;^UTILITY(U,$J,358.3,23067,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23067,1,3,0)
 ;;=3^Nonrheumatic Aortic Valve Stenosis
 ;;^UTILITY(U,$J,358.3,23067,1,4,0)
 ;;=4^I35.0
 ;;^UTILITY(U,$J,358.3,23067,2)
 ;;=^5007174
 ;;^UTILITY(U,$J,358.3,23068,0)
 ;;=I35.1^^105^1167^34
 ;;^UTILITY(U,$J,358.3,23068,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23068,1,3,0)
 ;;=3^Nonrheumatic Aortic Valve Insufficiency
 ;;^UTILITY(U,$J,358.3,23068,1,4,0)
 ;;=4^I35.1
 ;;^UTILITY(U,$J,358.3,23068,2)
 ;;=^5007175
 ;;^UTILITY(U,$J,358.3,23069,0)
 ;;=I42.1^^105^1167^37
 ;;^UTILITY(U,$J,358.3,23069,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23069,1,3,0)
 ;;=3^Obstructive Hypertrophic Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,23069,1,4,0)
 ;;=4^I42.1
 ;;^UTILITY(U,$J,358.3,23069,2)
 ;;=^340520
 ;;^UTILITY(U,$J,358.3,23070,0)
 ;;=I42.5^^105^1167^47
 ;;^UTILITY(U,$J,358.3,23070,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23070,1,3,0)
 ;;=3^Restrictive Cardiomyopathy NEC
 ;;^UTILITY(U,$J,358.3,23070,1,4,0)
 ;;=4^I42.5
 ;;^UTILITY(U,$J,358.3,23070,2)
 ;;=^5007196
 ;;^UTILITY(U,$J,358.3,23071,0)
 ;;=I42.8^^105^1167^14
 ;;^UTILITY(U,$J,358.3,23071,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23071,1,3,0)
 ;;=3^Cardiomyopathies NEC
 ;;^UTILITY(U,$J,358.3,23071,1,4,0)
 ;;=4^I42.8
